Breast cancer care in developing countries.

BACKGROUND: Breast cancer is the commonest cancer of women the world over, and its incidence is rising, especially in developing countries, where the disease poses a major health care challenge. This growing incidence in developing countries reflects the advanced stage at diagnosis, low levels of public awareness of the risk for the disease, and poor medical infrastructure and expertise, with the resultant poor treatment outcomes. METHODS: This article provides a collective edited summary of the presentations at the symposium titled "Breast Cancer Care in Developing Countries," held as part of the Breast Surgery International program at the International Surgical week 2007, Montreal, Canada, August 2007. The aim of the presentations was to bring out the diverse clinical pathological and outcomes-related facts of breast cancer care available to women in several countries. As the incidence of breast cancer continues to rise steadily in the developing world, the lack of awareness of this disease and the absence of breast cancer screening programs make it almost certain that the majority of breast cancers are diagnosed at an advanced stage. In addition, the quality of care available for breast cancer patients varies widely according to where the patient is treated. RESULTS: Though there are some centers of excellence providing multimodality protocol-based treatment on a par with the best anywhere in the world, most breast cancer patients receive inadequate and inappropriate treatment because of a lack of high-quality infrastructure-and sometimes skills-and, above all, because of limited financial resources. CONCLUSIONS: In countries where these limitations are present, there is a need to emphasize public health education, promoting early diagnosis. In addition, resources must be directed toward the creation of more public facilities for cancer treatment. As these goals are met, it is likely that there will be a much-needed improvement in breast cancer care in developing countries.

[Biliary stents for reconstruction in bile duct injuries. The role of bile acids]. / Férulas después de la reconstrucción de la vía biliar. El papel de los ácidos biliares.

UNLABELLED: Biliary stents, placed either surgically, endoscopically or radiologically are a frequent palliative and/or curative option for treatment of obstructive jaundice. Stones or sludge formation above or inside the stent are of major concern in that they cause dysfunction of the stent that needs prompt replacement. To evaluate the efficacy of ursodeoxycholic acid (UDCA) for long-term management of surgically placed biliary stents after iatrogenic injury, a prospective, controlled, randomized trial was conducted. METHOD: Patients with biliary tract reconstruction caused by iatrogenic injury that required a transanastomotic stent were randomized into a control group (N: 29) and into a UDCA (15 mg/kg day)-treated group (N: 30). Patients were followed on an external basis and a cholangiogram was obtained to verify stent patency. Liver function tests were also analyzed. RESULTS: The two groups were compared and no differences were observed. UDCA treated patients had significant elevation of transaminases and alkaline phosphatase. Two patients in the control group and four in the treated group developed lithiasis and/or sludge. CONCLUSION: No advantages were shown with administration of UDCA to maintain the biliary stents patent and to prevent neoformation of lithiasis and/or sludge. We conclude that no benefit is obtained with administration of UDCA to patients with biliary reconstruction and a transanastomotic stent.

To stent or not to stent bilioenteric anastomosis after iatrogenic injury: a dilemma not answered?

BACKGROUND: Bile duct injury is a complex and serious complication whose frequency has not diminished. A bilidigestive anastomosis (Roux-en-Y hepaticojejunostomy) is usually needed after complex injuries. Placement of an anastomotic stent is a matter of debate and to our knowledge there is no study that compares the results between stenting and not stenting the anastomosis. DESIGN: A retrospective review of medical records of patients operated on for biliary reconstruction after iatrogenic injury. SETTING: Tertiary care academic university hospital. PATIENTS: A comparative study was performed of patients operated on between 1995 and 1999, who were referred to our hospital for acute or elective reconstruction of the biliary tract following iatrogenic injury. All patients underwent Roux-en-Y hepaticojejunostomy. The patients were divided into 2 groups: those who underwent Roux-en-Y hepaticojejunostomy with a transanastomotic stent and those who underwent Roux-en-Y hepaticojejunostomy without a transanastomotic stent. MAIN OUTCOME MEASURES: Operative mortality, anastomotic dysfunction, biliary fistula, reoperations, postoperative complications, postoperative liver function tests. RESULTS: Sixty-three patients with high and complex biliary injuries (Bismuth type III, IV; Strasberg D, E). Thirty-seven cases had reconstruction with the placement of a transanastomotic stent and 26 did not have a stent placed. No operative mortality was observed. The postoperative outcomes of both groups were compared and no differences found. Good results were observed in more than 80% of the patients. Reoperations were more frequent in the nonstented group (15% vs. 5%) and complications were more frequent in the stented group (16% vs. 7%). CONCLUSIONS: Good results are obtained with a Roux-en-Y hepaticojejunostomy after complex injuries. The use of transanastomotic stents has to be selective according to the individual characteristics of each patient and the experience of each surgeon. We recommend their use when unhealthy (ie, ischemic, scarred) and small ducts (<4 mm) are found.